Cognition

Piracetam

Synthetic nootropic studied for age-related cognitive decline and memory, with mixed clinical results and unapproved supplement status in the US.

Piracetam

Piracetam

40
score
C
evidence
Caution
risk

Proven Benefits

01May improve cognition in age-relate
02May aid post-stroke aphasia recover
03May improve reading in dyslexia
04May enhance memory in healthy adult

Chemical Forms

Recommended
  • Piracetam
Avoid
  • Unlabeled racetam blends
  • Bulk powders without COA
Expert Note

Piracetam is a single synthetic molecule; no alternative salt forms offer superior absorption. Because it is not an approved dietary supplement in the US, products vary widely in purity; pharmacy-grade or third-party-tested material is preferable to unverified bulk powders.

Protocol

Amount
2400-4800 mg
Frequency
Split into 2-3 doses throughout the day
When
With meals to minimize gastrointestinal discomfort.

Condition-Based Dosing

Age-related cognitive impairment (older adults)
2400-4800 mg daily in divided doses for 12-24 weeks
Post-stroke aphasia (adjunctive)
4800 mg daily in divided doses, initiated under medical supervision
Healthy adults seeking cognitive enhancement
Not recommended; evidence does not support meaningful benefit.

Safety & Limits

Upper Safe Limit
No established UL; doses above 4800 mg/day have not shown additional benefit and may increase side effects.
Cycling
Safe for continuous use

Contraindications

Severe renal impairment — piracetam is renally excreted and accumulation risk increases
Hemorrhagic stroke or bleeding disorders — may affect platelet function
Pregnancy and breastfeeding — insufficient safety data

Synergies

Piracetam increases acetylcholine demand; adequate choline intake may reduce the risk of headaches associated with racetam use.

Provides choline and cytidine, which may complement piracetam’s cholinergic mechanism.

Avoid Combining With

  • Alcohol (may compound cognitive impairment and increase side effects)
  • Warfarin or antiplatelet drugs — may increase bleeding risk in susceptible individuals
Updated Invalid Date